0
No hay productos en el carro de la compra
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Casa > Kits > Spike RBD > EP-115

SARS-CoV-2 (B.1.1.529) Inhibitor Screening Kit (Spike RBD)

For research use only.

Order Now

IDComponentsSize
EP115-C01Pre-coated Human ACE2 Microplate1 plate
EP115-C02SARS-CoV-2 Inhibitor20 μg
EP115-C03HRP-SARS-CoV-2 Spike RBD(B.1.1.529)15 μg
EP115-C0410xWashing Buffer50 mL
EP115-C05Dilution Buffer50 mL
EP115-C06Substrate Solution12 mL
EP115-C07Stop Solution7 mL
  • Background
    As of Nov 29th, confirmed cases of a new variant of concern (VOC) B.1.1.529 have been reported in South Africa, Botswana and more than 12 other countries. Thanks to the rapid sequencing efforts of South African scientists, the whole world is now alerted about this potentially devastating lineage, which was assigned the name Omicron by WHO.Omicron is a highly divergent variant with a high number of mutations (26-35) in the spike. Identification of some familiar mutations that also appeared on other VOCs gives rises to concerns of its immune escape potential and higher transmissibility,it is necessary to develop SARS-CoV-2 inhibitors, such as vaccines,therapeutic antibodies and small molecule compounds against SARS-CoV-2(B.1.1.529). The SARS-CoV-2 (B.1.1.529) Inhibitor Screening Kit (Spike RBD) is helpful to develop the to test SARS-CoV-2 inhibitors.
  • Application

    This kit is developed for screening inhibitors of SARS-CoV-2 (B.1.1.529).

    It is for research use only.

  • Reconstitution
    Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
  • Storage & Shipping
    1. Unopened kit should be stored at 2℃-8℃ upon receiving.

    2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.

    3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

    Shipping Statement

  • Assay Principles
    This assay kit is used to measure the levels of Anti-SARS-CoV-2 neutralizing antibody through a competitive ELISA. The microplate in the kit has been pre-coated with Human ACE2 protein. First samples are added to the wells followed by addition of HRP-SARS-CoV-2 Spike RBD. After incubation, the wells are washed and substrate is added to the wells. The reaction is terminated by the addition of stop solution and the intensity of color is measured at 450 nm. The presence of neutralizing antibodies in samples will compete with ACE2 for HRP-SARS-CoV-2 Spike RBD binding. The intensity of assay signal decrease proportionally to the presence of Anti-SARS-CoV-2 neutralizing antibody.

    Your experiment will include 5 simple steps:

    a) All reagents were returned to room temperature(20°C-25°C) before use.

    b) Make series the tested sample and SARS-CoV-2 Inhibitor with ditlution buffer, HRP-SARS-CoV-2 RBD diluted with dilution buffer.

    c) Add the diluted sample, Control and the HRP-SARS-CoV-2 RBD add the plate respectively.

    d) Wash the plate and add TMB or other colorimetric HRP substrate.

    e) Stop the substrate reaction by add diluted acid. Absorbance (OD) is calculated as the absorbance at 450 nm minus the absorbance at 630 nm to remove background prior to statistical analysis. The OD Value reflects the amount of antibody bound.

Typical Data Please refer to Ds document for the assay protocol.
 Spike RBD TYPICAL DATA

Incubation of SARS-CoV-2 inhibitor:Blocking the binding of HRP-SARS-CoV-2 Spike RBD(B.1.529) to Human ACE2.
Serial dilutions of SARS-CoV-2 inhibitor (Catalog # EP115-C02) (1:1 serial dilutions, from 25ug/mL to 0.049ug/mL(171.9nM to 0.34nM)) and loaded onto the plate coated by human ACE2 in the presence of HRP-SARS-CoV-2 Spike RBD(B.1.1.529). Background was subtracted from data points prior to log transformation and curve fitting.

  • Clinical and Translational Updates

Comments (0)


ETA de productos en stock: 2 días laborables

Price(EUR) : €660.00

Promotion & Exhibitions



Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Email
Correo electrónico
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Dejar un mensaje